<DOC>
	<DOCNO>NCT01021865</DOCNO>
	<brief_summary>The overall goal proposal determine effect acute hyperglycemia modulation Glucagon-like Peptide-1 ( GLP-1 ) myocardial perfusion type 2 diabetes ( DM ) . This study plan utilize myocardial contrast echocardiography ( MCE ) explore ) effect acute hyperglycemia myocardial perfusion coronary flow reserve individual without DM ; b ) effect GLP-1 myocardial perfusion coronary flow reserve euglycemia hyperglycemia DM . The investigator recruit individual without DM match age , gender degree obesity . The investigator measure myocardial perfusion rest vasodilator stress ( ascertain coronary flow reserve ) subject control pancreatic clamp condition euglycemia ( glucose ~100 mg/dl ) hyperglycemia ( glucose ~250 mg/dl ) presence absence concomitant GLP-1 infusion . The investigator believe translational significance study immense , impact upon acute chronic cardiovascular disease manifestation . The effect glycemic control cardiovascular outcome , morbidity mortality remain area active investigation , fuel recent conflict result several large clinical trial ( ACCORD , United Kingdom Prospective Diabetes Study ( UKPDS ) , ADVANCE , VADT ) . If investigator find hyperglycemia associate altered myocardial perfusion , mechanistic implication prevention management acute chronic cardiovascular disease DM groundbreaking . Furthermore , GLP-1 augments myocardial perfusion ( peripheral vasculature ) , therapeutic benefit prevention cardiovascular event predispose population clear .</brief_summary>
	<brief_title>Effects Hyperglycemia Myocardial Perfusion Humans With Without Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Regadenoson</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Males female Age 4060 year BMI &lt; = 35 kg/m2 Diabetic subject HbA1c concentration &lt; = 8 % . Diabetic subject either diet lifestyle therapy alone , monotherapy metformin sulphonylureas ( except glyburide ) . All diabetic subject stable dose oral agent therapy 3 month prior enrollment . Subjects cerebrovascular peripheral vascular disease . Subjects suspect overt autonomic neuropathy . Diabetic subject thiazolidinediones , insulin , GLP1 base therapy ( exenatide sitagliptin ) , alphaglucosidase inhibitor , glyburide combination antidiabetic drug therapy . Diabetics microalbuminuria .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>GLP-1</keyword>
	<keyword>Myocardial contrast echocardiography</keyword>
	<keyword>Myocardial perfusion</keyword>
</DOC>